Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
$0.35
$0.35
$0.17
▼
$0.40
$94.74M1.372.03 million shsN/A
CapsoVision, Inc. stock logo
CV
CapsoVision
$6.76
+1.7%
$6.54
$4.50
▼
$15.37
$362.94M-2.34230,027 shs42,140 shs
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
$1.34
+1.1%
$2.56
$1.12
▼
$6.79
$269.31M-1.5275,898 shs22,376 shs
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$4.48
+0.9%
$4.42
$1.17
▼
$5.44
$293.45M1.59610,851 shs37,644 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
0.00%0.00%0.00%0.00%0.00%
CapsoVision, Inc. stock logo
CV
CapsoVision
+2.78%+4.40%+1.84%+8.66%+25.95%
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
-1.48%-17.39%-47.43%-63.06%-78.99%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
+0.45%-9.02%+14.73%-2.63%+53.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
$0.35
$0.35
$0.17
▼
$0.40
$94.74M1.372.03 million shsN/A
CapsoVision, Inc. stock logo
CV
CapsoVision
$6.76
+1.7%
$6.54
$4.50
▼
$15.37
$362.94M-2.34230,027 shs42,140 shs
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
$1.34
+1.1%
$2.56
$1.12
▼
$6.79
$269.31M-1.5275,898 shs22,376 shs
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$4.48
+0.9%
$4.42
$1.17
▼
$5.44
$293.45M1.59610,851 shs37,644 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
0.00%0.00%0.00%0.00%0.00%
CapsoVision, Inc. stock logo
CV
CapsoVision
+2.78%+4.40%+1.84%+8.66%+25.95%
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
-1.48%-17.39%-47.43%-63.06%-78.99%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
+0.45%-9.02%+14.73%-2.63%+53.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
0.00
N/AN/AN/A
CapsoVision, Inc. stock logo
CV
CapsoVision
2.25
Hold$9.5040.45% Upside
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
1.00
Sell$7.00420.83% Upside
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
2.40
Hold$6.1737.68% Upside

Current Analyst Ratings Breakdown

Latest ASXC, TMCI, SSII, and CV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
DowngradeSell (D-) ➝ Sell (E+)
11/9/2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
UpgradeHold ➝ Buy$4.50 ➝ $6.50
11/9/2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
UpgradeNeutral ➝ Buy
10/15/2026
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
Reiterated RatingSell (E+)
9/25/2026
CapsoVision, Inc. stock logo
CV
CapsoVision
Reiterated RatingSell (D-)
8/31/2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
UpgradeSell (E+) ➝ Sell (D-)
8/31/2026
CapsoVision, Inc. stock logo
CV
CapsoVision
UpgradeHold
8/28/2026
CapsoVision, Inc. stock logo
CV
CapsoVision
Initiated CoverageBuy$9.00
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
$8.58M11.04N/AN/A$0.13 per share2.68
CapsoVision, Inc. stock logo
CV
CapsoVision
$13.55M26.76N/AN/A$0.49 per share13.80
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
$42.49M6.34N/AN/A$0.20 per share6.72
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$212.69M1.38N/AN/A$0.94 per share4.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
-$78.43M-$0.31N/AN/AN/A-902.25%-184.10%-114.75%N/A
CapsoVision, Inc. stock logo
CV
CapsoVision
-$25.32M-$0.47N/AN/AN/A-210.09%-160.23%-122.59%N/A
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
-$12.13M-$0.06N/AN/AN/A-23.73%-26.77%-15.01%N/A
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-$59M-$0.86N/AN/AN/A-27.44%-72.99%-29.19%N/A

Latest ASXC, TMCI, SSII, and CV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/A-$0.03N/A-$0.03N/A$6.33 million
11/12/2026Q3 2026
CapsoVision, Inc. stock logo
CV
CapsoVision
-$0.15-$0.15N/A-$0.15N/A$3.57 million
11/6/2026Q3 2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-$0.2540-$0.19+$0.0640-$0.19$47.80 million$48.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
N/AN/AN/AN/AN/A
CapsoVision, Inc. stock logo
CV
CapsoVision
N/AN/AN/AN/AN/A
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/AN/AN/AN/AN/A
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
N/A
1.00
0.69
CapsoVision, Inc. stock logo
CV
CapsoVision
N/A
5.07
2.44
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/A
2.24
1.66
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
0.91
2.58
1.66

Institutional Ownership

CompanyInstitutional Ownership
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
9.35%
CapsoVision, Inc. stock logo
CV
CapsoVision
N/A
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/A
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
84.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Asensus Surgical, Inc. stock logo
ASXC
Asensus Surgical
170272.33 million264.52 millionNot Optionable
CapsoVision, Inc. stock logo
CV
CapsoVision
9953.61 million48.90 millionN/A
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
483200.38 millionN/AN/A
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
45065.56 million50.21 millionOptionable

Recent News About These Companies

Treace Medical Concepts Shares Rise After Stifel Upgrade
Treace Medical (TMCI) Q3 2026 Earnings Call Transcript
Treace to Present at the Stifel 2026 Healthcare Conference
Treace Medical Wilts Ahead of Q3 Figures

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Asensus Surgical stock logo

Asensus Surgical NYSEAMERICAN:ASXC

$0.35 0.00 (0.00%)
As of 08/22/2024

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

CapsoVision stock logo

CapsoVision NASDAQ:CV

$6.76 +0.11 (+1.71%)
As of 11:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease. The capsule acquires and stores video images in onboard memory while moving through the GI tract, and the software component allows healthcare providers to view the video retrieved from the capsule—either by streaming it from the cloud, where it is securely stored, to anywhere, at their convenience, using our CapsoCloud software, or downloading it from the capsule themselves and reviewing it in our CapsoView software. The CapsoCam is a wire-free capsule endoscopy solution, eliminating patient-worn data recorders and providing clinicians a zero-capex, maintenance-free, flexible, and scalable workflow. The CapsoCam Plus is classified as a Class II device and has received FDA marketing authorization through the 510(k)-clearance process. We are (i) in the process of updating CapsoCam Plus to add our self-developed AI assisted reading technology and (ii) targeting related FDA 510(k) and EU submissions in the second half of 2025 and clearance of the updated capsule by the end of 2025, with commercialization shortly thereafter. Our AI assisted reading tools detect and highlight suspected abnormalities for a clinician, reducing their time to review the video and making capsule endoscopy more financially attractive to their practice. Our 510(k) submission and FDA review thereof may be delayed and we may not receive 510(k) clearance from the FDA on a timely basis or at all. We began sales of our small-bowel capsule system to our provider customers (i.e., primarily gastroenterologists practicing in clinics and/or hospitals) both internationally (in 2012) and in the U.S. (in 2017) through our global sales and marketing team. In the U.S., we sell to customers directly. Internationally, we sell both directly and through qualified exclusive distributors in specified regions. Our largest international markets (based on shipping destination) are France, Germany, and Canada. In 2023, we established a direct sales team in Germany to better serve our customers and strengthen our market presence in this key market. We plan to (i) further grow our existing sales and marketing team to increase small-bowel-related sales and (ii) leverage our existing sales and marketing team to sell future product additions to our GI-tract capsule endoscopy solution. Our revenue has increased in each year since we began U.S. direct sales in 2020. Our revenues for the years ended December 31, 2023 and 2024 totaled approximately $9.8 million and $11.8 million, respectively, representing a year-over-year growth of approximately 21%. Our revenues for the three months ended March 31, 2024 and 2025 totaled approximately $2.5 million and $2.8 million, respectively, representing a year-over-year growth of approximately 12%. The primary driver for our revenue growth was an increase in the number of CapsoCam Plus capsules sold: an increase of 19% from 2023 to 2024 and 11% from the three month period ended March 31, 2024 to the three month period ended March 31, 2025, with an increase in unit sales of 26% in the U.S. and 4% internationally from 2023 to 2024 and 10% in the U.S. and 13% internationally from the three month period ended March 31, 2024 to the three month period ended March 31, 2025. In 2023 and 2024, international sales accounted for 26% and 23% of total revenue. In the three-month periods ended March 31, 2024 and 2025, international sales accounted for 23% of total revenue. As of March 31, 2025, our small bowel capsule has been used in more than 135,000 patients worldwide and for 2024 our customer retention rate was approximately 90%. All of our revenues to date have been, and in the near-term will continue to be, generated from CapsoCam Plus related sales for the small bowel; and our ability to grow our small-bowel-related revenue is subject to our ability to successfully and timely execute related elements of our revenue growth strategy, including being able to compete effectively against our competitors (including those with an existing FDA-cleared product and that have established a market presence). To expand beyond small-bowel-related sales, we are developing our next pipeline capsule endoscope product, CapsoCam Colon. Our CapsoCam Colon capsule (i) leverages CapsoCam Plus’s existing capsule design with its panoramic view and (ii) incorporates both our self-developed AI to automatically detect polyps in the video and our polyp-size measurement tool enabled by a 3D sensor in the capsule (polyp size being highly correlated with a polyp’s risk of becoming cancer). Based on our current regulatory development plan, we are targeting CapsoCam Colon revenues beginning, in the U.S., in the second half of 2026 after receiving FDA 510(k) clearance, and in the EU, in early 2027 after receiving a CE Mark, of our second generation of CapsoCam Colon system, designed with a larger field of view and better image quality to improve accuracy, and which would be classified as a Class II device. We recently submitted our 510(k) for the first generation of our CapsoCam Colon. FDA review of our 510(k) submissions may be delayed and we may not receive 510(k) clearances from the FDA on a timely basis or at all. Longer term, we believe our CapsoCam family of products, incorporating our panoramic imaging solution, can be adapted to address new GI medical indications. Potential new medical indications include esophageal medical conditions (such as esophageal varices and Barrett’s esophagus) and pancreatic cancer. We plan to commence feasibility studies of CapsoCam’s accuracy in (i) screening esophageal varices (i.e. enlarged blood veins in the esophagus) in cirrhotic patients with portal hypertension in the second half of 2025 and (ii) detecting abnormalities indicative of cancerous and precancerous pancreatic neoplasia (abnormal cell growth) in the first half of 2026, in each case, subject to timely availability of sufficient funding and liquidity and/or potential adjustment of our clinical development priorities. Our ability to pursue our growth strategies is subject to our ability to timely and successfully meet our cash and liquidity needs (through this offering, cash generated from operations and the issuance of additional equity securities or borrowings). These efforts may be adversely impacted by our history of operating losses, accumulated deficit, and substantial doubt about our ability to continue as a going concern qualification as stated in the footnotes to our financial statements. We were incorporated under the laws of the State of Delaware on August 1, 2005, under the name “Capso Vision, Inc.” and changed our name to CapsoVision, Inc. on May 31, 2016. Our principal executive office is located in Saratoga, CA.

SS Innovations International stock logo

SS Innovations International NASDAQ:SSII

$1.34 +0.01 (+1.05%)
As of 11:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.

Treace Medical Concepts stock logo

Treace Medical Concepts NASDAQ:TMCI

$4.48 +0.04 (+0.88%)
As of 11:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.